Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05MFO
|
|||
| Former ID |
DNC004111
|
|||
| Drug Name |
MDL-11939
|
|||
| Synonyms |
Glemanserin; 107703-78-6; alpha-Phenyl-1-(2-phenylethyl)-4-piperidinemethanol; MDL 11,939; Mdl 11939; Mdl-11,939; MDL-11939; Glemanserin [USAN:INN]; CHEMBL18972; 132553-86-7; 4-Piperidinemethanol, alpha-phenyl-1-(2-phenylethyl)-; 4-Piperidinemethanol, alpha-phenyl-1-(2-phenylethyl)-, (+-)-; (+-)-1-Phenethyl-alpha-phenyl-4-piperidinemethanol; AC1L2GSP; Glemanserin (USAN/INN); ( inverted exclamation markA)-1-phenethyl-a-phenyl-4-piperidinemethanol; GTPL186; SCHEMBL120012; AC1Q771C; DTXSID4042624; CTK8D3348; CHEBI:91790
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Discontinued in Phase 3 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H25NO
|
|||
| Canonical SMILES |
C1CN(CCC1C(C2=CC=CC=C2)O)CCC3=CC=CC=C3
|
|||
| InChI |
1S/C20H25NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19-20,22H,11-16H2
|
|||
| InChIKey |
AXNGJCOYCMDPQG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 107703-78-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6797184, 8194826, 14898173, 43128054, 47206247, 47359954, 47954521, 50064132, 50193113, 56311668, 57318359, 85210532, 85788118, 91746356, 103064544, 103077094, 103184480, 103918010, 104351286, 117612643, 126424413, 126678986, 127473340, 134221813, 134341316, 135030226, 135287998, 135650574, 135698212, 137239955, 137239956, 142572591, 143344450, 162022664, 162221881, 163108262, 179149554, 184536608, 184547728, 204369769, 223654227, 224897292, 226491673, 241181941, 241377505, 252345049
|
|||
| ChEBI ID |
CHEBI:91790
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | |||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 186). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000314) | |||
| REF 3 | Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992 Dec 25;35(26):4903-10. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.